

Unlocking the Full Potential of the Immune System Against Cancer

Investor Presentation

June 1, 2025



This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be predictive of the results of the clinical trials currently under way, (ii) regulatory authorities will agree with the Company's further development plans for its therapies, or (iii) the Company will find development and commercialization partners for its therapies in a timely manner and on satisfactory terms and conditions, if at all. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results and development.

For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risques") section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene's website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.



Transgene in a Snapshot



Unique and highly potent viral vector-based immunotherapies Lead program TG4050 to deliver data and create significant value in early setting solid tumors between 2025 and 2028


 $\langle \mathbf{O} \rangle$

Additional programs and R&I activity to deliver news flow and fuel Transgene's portfolio in the mid term



myvac® – A Novel Individualized Cancer Immunotherapy Platform





- Building upon proof of principle of TG4050, leading myvac[®]-based cancer vaccine: Randomized Phase II part currently enrolling patients based on very promising Phase I data
- Potential further acceleration based on innovation in the adjuvant setting of operable Head & Neck cancer and other early-stage indications

*Source: C. Le Tourneau, **"Randomized Phase I trial of adjuvant personalized** cancer vaccine TG4050 in resected locally advanced head and neck squamous cell carcinoma (HNSCC) patients", <u>ASCO</u> - June 2025, rapid oral presentation



Product	Indication	Collaboration	Discovery	Phase I	Phase II		
LEAD ASSET: II	NDIVIDUALIZED NEO	ANTIGEN CANCER V	ACCINES (r	nyvac® p	latform)		
TG4050 myvac	Individualized neoantigen therapy	Head and neck cancer (adjuvant)		R	R	 Phase I (n = 32) No relapse in treatment arm with at lead follow up for all patients Durable immunogenicity Phase II (n ≈ 50) Completion of enrollment (Q2 2025) Completion of randomization (Q4 2025) 	\Orchestrating a brighter wor
		Other indication				Additional Ph. I trial to start (Q4 2025)	
Other viral ve	ctor-based assets						
TG4001	Shared antigens cancer vaccine	Cervical and anogenital HPV+ cancers			R	Assessing potential partnership opportunities in HPV+ indications	
BT-001 invir	Oncolytic virus	Solid tumors (IT*)				Updated data expected (H2 2025)	BioInvent
TG6050 invir(Oncolytic virus	Lung cancer (IV*)				Initial data expected (Q2 2025)	
Research & innovation	Internal programs						

*IV: intravenous administration IT: intratumoral administration R: randomized

transgene





1

Neoantigen Therapeutic Cancer Vaccine

Focused on delivering the promise of individualized cancer vaccine

myvac[®] - TG4050 | Combines Unique Know How and Expertise

ransgene



Strongly immunogenic vector

- Demonstrated capability to express complex antigen structures and have them presented by APCs
- Ability to elicit strong, durable and specific immune
- response
- **O** Established safety profile

Rapid, integrated and scalable manufacturing process – Ongoing progress



one patient • one genome

one vaccine

Clinically-validated Artificial Intelligence & Bioinformatics powered approach

Neoantigen identification

BiolT

- Based on multiple parameters to identify neoantigens from whole tumor exome analysis*
 NEC's AL and machine learning environment
- NEC's AI and machine learning environment

Optimal neoantigen display

- VacDesignR[®] for optimal design of the recombinant virus
- Improve vaccine production
- Property of Transgene

Al powered and cutting-edge software environment

Dedicated tools for TG4050 end-to-end production

Technology well suited for early setting solid tumors to prevent relapse after/with standard treatment








*Source: Mallone et al., "Performance of neoantigen prediction for the design of TG4050, a patient-specific neoantigen cancer vaccine", <u>AACR</u>, June 2020, Poster presentation



TG4050 | Operable Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy



TG4050 | Phase | Data – Compelling Data in High-Risk Patient Population

Patient Characteristics	Arm A (N=17*) TG4050 single agent	Arm B (N=16) Watchful waiting
Male / Female, n (%)	11 (65%) / 6 (35%)	13 (81%) / 3 (19%)
Age (years), median (range)	61 (26 – 79)	57 (47 – 74)
ECOG PS 0 / 1, n (%)	12 (71%) / 5 (29%)	9 (56%) / 7 (44%)
Primary tumor location Oral cavity Oropharynx Hypopharynx Larynx	14 (82%) 2 (12%) 1 (6%)	10 (63%) 2 (13%) 3 (19%) 1 (6%)
Clinical stage, n (%) III IVa	7 (41%) 10 (59%)	3 (20%) 13 (81%)
Pathological stage, n (%) I/II III IVa IVb	1 (6%) 4 (24%) 7 (41%) 5 (29%)	1 (6%) 3 (19%) 5 (31%) 7 (44%)
Concomitant cisplatin, n (%)	10 (59%)	9 (56%)


Pathological Risk Factors	Arm A (N=17*) TG4050 single agent	Arm B (N=16) Watchful waiting
Extracapsular effraction, n (%)	5 (29%)	8 (50%)
Invaded margins, n (%)	4 (24%)	3 (19%)
Perineural infiltration, n (%)	13 (77%)	7 (44%)
4+ invaded lymph nodes, n (%)	2 (12%)	3 (19%)
No. of risk factors, n (%) 0 1 2+	3 (18%) 5 (29%) 9 (53%)	2 (13%) 9 (56%) 5 (31%)

* **17** patients evaluable for demographic and safety / **16** patients evaluable for DFS **Minimum exposure not met: the 1 patient non evaluable for DFS** was diagnosed with locoregional recurrence after only 2 administrations of TG4050

Source: C. Le Tourneau, "Randomized Phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced head and neck squamous cell carcinoma (HNSCC) patients", <u>ASCO</u> - June 2025, rapid oral presentation ANNUAL MEETING


TG4050 | Phase | Data – 100% DFS 2 Years after Treatment Initiation

Clinical Proof of Principle in Adjuvant Setting



- TG4050 | Phase | Data - Persistent Specific Cellular Response Following Vaccination

CD8 T cell responses persist over one year after the end of treatment (M24)




 Patients displayed sustained neoantigenspecific CD8+ responses against multiple selected targets

 Neoantigen-specific CD8 T cell responses to multiple vaccine epitopes

Arm B

Start of TG4050

at recurrence





*Source: C. Le Tourneau, **"Randomized Phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally** advanced head and neck squamous cell carcinoma (HNSCC) patients", <u>ASCO</u> - June 2025, rapid oral presentation 11

TG4050 | Potential to Extend Remission Period and Address Significant Medical Need

Head & Neck program


- Positive Phase I part 100% 24-month DFS
- Ongoing Phase II part Last patient to be randomized in Q4 2025
- **Potential acceleration** in evolving treatment landscape

Expansion in other early-setting cancer indications with high risk of relapse



Could address other solid tumors in perioperative settings w or w/o ICIs – Significant market opportunity

Additional Ph. I trial to start in Q4 2025 in new indication






Other Viral Vector-Based Assets

Rapidly Generating Multiple Virus-Powered Off-the-Shelf Drug Candidates Targeting Solid Tumors Our **Oncolytic Viruses** (OV) – Combined Effects of Vector, Payload and Immune Stimulation Compelling Clinical Data Support Intravenous (IV) Route of Administration

invir



Patented Backbone VV_{cop}TK⁻RR⁻ vector with multiple competitive advantages:

O Encode numerous and various payloads
 A statement of the stat

O Multiple routes of administration (IV, IT, locoregional) and extend OV market beyond IT administration

- Potential to target multiorgan lesions and warm up TME
- O Address broad range of solid tumors

Proof of principle obtained

- Good safety profile
- Able to reach tumors, selectively replicate and express payload, incl. via intravenous administration

Goal: to target multiorgan lesions and reverse tumor resistance

14

BT-001 | Promising Antitumor Activity of OV Armed with Anti-CTLA4 Ab + GM-CSF Completed Phase I/IIa Trial Assessing IT Route of Administration

The right virus + payload

VV_{cop}TK⁻RR⁻ oncolytic armed with **BioInvent**'s potent **anti-CTLA4 Ab + GM-CSF**

- o Activates and increases T-effector cells
- Treg depleting activity
- Stimulates immune cells (incl. APC)

Completed Phase I (NCT04725331) monotherapy and combination w. anti-PD1

- Ph. I part B (pembrolizumab combination)
 Enrolment completed
- **Additional data expected in H2 2025**





Promising antitumor activity*

monotherapy and combination w. anti-PD1

- → Converts the TME from "cold" to "hot"
- → Replicates and persists in tumor tissue
- → Anti-CTLA4 expressed in the tumor with no detectable systemic exposure
- → Partial responses in 2/6 patients (combination regimen) & stable disease in 4/18 patients (monotherapy)
- → Tumor shrinkage in injected and non-injected lesions

Can be developed for multiple cancer indications



Collaboration with MSD which provides pembrolizumab (KEYTRUDA®)



15

ongress *Champiat et al, "Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors" <u>ESMO</u> 2024, September 14, 2024, Poster presentation

TG6050 Administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor

Ongoing Phase I Trial to Assess Systemic Route of Administration



Initial goal

demonstrate potential of IV administration in "cold", non-resectable metastatic tumors

Oncolytic armed with IL-12 and anti-CTLA4 Ab

- P Triggers a powerful antitumor immune response
- Restores the immune defenses within the tumor
- Outstanding preclinical data* (strong antitumor activity) remodeling TME (AACR 2023 and JITC, July 2024)

Phase I trial - Indication: metastatic and PD1 failed tumors




- Advanced or metastatic NSCLC after failure with available treatment options, including anti-PD1/PD-L1 Intravenous (IV) administration Inclusions completed (NCT: 05788926)
- Initial data (single agent) in Q2 2025 Could be combined with ICIs

Potential to address a major oncology market

*Azar et al, TG6050, "TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment" <u>JITC</u>, July 2024 16

TG4001 | Phase II Trial in Patients with HPV16⁺ Cervical and Anogenital cancer




Top line data

- Primary objective (improvement in progression-free survival) not met in the overall patient population
- Positive efficacy trend in cervical cancer patients observed in preplanned subgroup analysis
- Assessing potential partnership opportunities in HPV+ indications

Source: C. Le Tourneau *et al.*, **"Randomized Phase II trial evaluating the** combination of TG4001, an HPV16 therapeutic cancer vaccine and avelumab in patients with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer", <u>ASCO</u> - June 2025, poster pres.


Treated in 1st line or in 2nd line (with a maximum of 1 prior systemic chemotherapy) Checkpoint-blocker naïve, without liver metastasis at baseline Including all levels of PD-L1 expression





Outlook





Company Funded to Deliver Multiple Value Generating Milestones

Business funded until the end of April 2026

Enables Transgene to deliver significant milestones with *myvac*[®] platform and other viral vector-based immunotherapies

| Neoantigen vaccine – TG4050

Proof of principle

myvac

- already obtained in Head and Neck cancer (adjuvant)
- Clinical benefit for patients and strong immunogenicity, persistent cellular immune response
- Ongoing randomized Phase I/II (head and neck cancer) 80 patients overall
 - → <u>Ph. I part</u>: 36-mo. follow-up data expected in **H1 2026**
 - Ph. II part: randomization of the last patient in Q4 2025

Other indication

→ Plan to launch **new Phase I** in additional indication in **Q4 2025**

Other viral vector-based assets

O BT-001: Phase I data presentation (H2 2025)

O TG6050: Initial Phase I data (Q2 2025)

O TG4001: Assessing potential partnership opportunities in HPV+ indications

19



Appendices

New Leadership to Take Transgene to the Next Level



ALESSANDRO RIVA, MD Chairman & CEO

30+ years experience





CHRISTOPHE ANCEL, PharmD VP, Chief Quality Officer and Qualified Pharmacist



EMMANUELLE DOCHY, MD VP, Medical Affairs, Chief



JOHN FELITTI VP, Legal, General Counsel and Chief Compliance Officer

MAURIZIO CEPPI, PhD

VP, Chief Scientific Officer



LUCIE LARGUIER VP, Chief Financial Officer



CHRISTELLE SCHWOERER VP, Human Resources




SIMONE STEINER VP, Chief Technical Officer



JAMES WENTWORTH VP, Chief Business Officer



TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities Combines Bioengineering and Digital Transformation




transgene


TG4050 | Phase I data – Promising Signals of Clinical Activity in Adjuvant Setting



32 patients randomized (R) – As of April 2025



TG4050 | Phase I data – Generates and/or Expands Tumor Specific T Cells



Source: G. Le Tourneau *et al.*, **"Randomized Phase I Trial of** Adjuvant Individualized TG4050 Vaccine in Patients with Locally Advanced Resected HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)", <u>SITC</u> November 2024, Poster presentation

transgene

Exploration of Tumor TME

TME: tumor micro-environment, TMB: tumor mutational burden, F: fibrotic, NF: non-fibrotic

Arm A: TG4050 single agent

PD-L1	TMB (mt/Mb)	TME functional class	Tumor cell proliferation
Medium	3.19	Immune Desert	Medium
Medium	1.99	Immune Desert	Low
Medium	4.34	Imm. Enriched, NF	Medium
Low	3.28	Immune Desert	Medium
Medium	3.42	Immune Desert	Medium
Medium	1.9	Imm. Enriched, NF	Low
Medium	3.16	Fibrotic	Medium
Low	4.2	Immune Desert	Medium
Medium	1.99	Imm. Enriched, F	Low
Medium	4	Imm. Enriched, NF	Low
High	1.37	Imm. Enriched, NF	Medium
Low	2.41	Immune Desert	High
Low	3.05	Immune Desert	Medium
Medium	7.7	Imm. Enriched, F	Medium
Medium	1.68	Imm. Enriched, NF	Medium
Medium	1.46	Immune Desert	Low

Challenging population with high prevalence of low/negative PD-L1 expressors and relatively poor pro-immune infiltrates

Arm B: Control arm

Medi

PD-L1	TMB (mt/Mb)	TME functional class	Tumor cell proliferation	
Vedium	3.02	Immune Desert	Medium	
Vedium	1.6	Immune Desert	Medium	Source: G. Le To et al., "Rando
Low	4.26	Immune Desert	Medium	Phase I Tria Adjuvant Individ
Vedium	3.02	Immune Desert	Medium	TG4050 Vaccir Patients with
Medium	3.36	Immune Desert	Medium	Advanced Re HPV-negative He
High	3.28	Imm. Enriched, NF	High	Neck Squamou Carcinoma (HI
Low	3.64	Immune Desert	Medium	<u>SITC</u> November Poster presentati
Medium	7.95	Fibrotic	Low	(sitc)
Medium	1.9	Immune Desert	Medium	SILC
Medium	0.34	Immune Desert	Medium	
Medium	2.77	Immune Desert	Medium	
Medium	5.24	Immune Desert	Low	
Medium	2.91	Imm. Enriched, NF	Medium	
Medium	0.03	Imm. Enriched, NF	Medium	
Low	2.1	Immune Desert	Medium	transport
Medium	3.56	Immune Desert	Medium	transgene

rce: G. Le Tourneau al., "Randomized Trial of se want Individualized Vaccine in 050 ients with Locally Resected anced /-negative Head and k Squamous Cell cinoma (HNSCC)", November 2024, ter presentation

25

Environmental, Social and Governance Commitments



Transgene's **ESG** strategy is based on 6 commitments

To patients

- To our partners
- To our **employees**
- To our shareholders and investors
- To society and the regions
- To the **planet**

TOP 5 French companies with the **best ESG performance** for 2023*.

85/100

Gaïa EthiFinance Award (+8 pts)

ESG rating higher than industry benchmark (Pharma/Biotech) 44/100

Vigeo Eiris (+20 pts)

99/100 Equal Employment Index (+4 pts)


26

transgene



[/]*with < 250 employees, according to the Gaia EthiFinance 2024 Award study <u>LinkedIn</u> / <u>Website</u>







CONTACT

Lucie Larguier Chief Financial Officer

investorrelations@transgene.fr

400 Boulevard Gonthier d'Andernach | Parc d'Innovation | CS80166 67405 Illkirch Graffenstaden Cedex | France Tél.: + 33 (0)3 88 27 91 21 | www.transgene.fr